北大医药(000788) - 2021 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2021 reached ¥590,092,977.81, an increase of 4.48% year-over-year, while the year-to-date revenue was ¥1,693,912,427.73, up 21.67% compared to the same period last year[3]. - Net profit attributable to shareholders for Q3 2021 was ¥22,593,175.48, representing a 41.05% increase year-over-year, and year-to-date net profit was ¥55,512,494.80, up 44.87%[3]. - The basic earnings per share for Q3 2021 was ¥0.0379, a 40.92% increase compared to the same period last year, with diluted earnings per share also at ¥0.0379[3]. - Total operating revenue for the third quarter of 2021 reached ¥1,693,912,427.73, an increase of 21.7% compared to ¥1,392,206,192.61 in the same period last year[22]. - The total profit for Q3 2021 was CNY 70,963,914.43, up from CNY 48,104,350.73 in Q3 2020, which is an increase of approximately 47.3%[23]. - Net profit for Q3 2021 reached CNY 55,518,176.84, compared to CNY 38,315,910.60 in Q3 2020, reflecting a growth of about 44.9%[23]. Assets and Liabilities - The company's total assets as of the end of Q3 2021 were ¥2,390,098,431.34, reflecting a 3.64% increase from the end of the previous year[3]. - The total liabilities as of September 30, 2021, were ¥1,043,107,302.87, compared to ¥1,014,727,869.44 at the end of 2020, representing an increase of 2.8%[20]. - The company's cash and cash equivalents decreased to ¥452,620,643.52 from ¥476,959,296.66, a decline of 5.1%[18]. - Accounts receivable increased to ¥1,254,180,192.37, up 7.8% from ¥1,163,039,543.29 at the end of 2020[18]. - The company's total equity attributable to shareholders increased by 4.28% to ¥1,352,520,226.16 compared to the end of the previous year[3]. - The total equity attributable to shareholders was approximately CNY 1.29 billion, with retained earnings of CNY 448.93 million[31]. Research and Development - Research and development expenses for the first nine months of 2021 amounted to ¥19,671,088.05, a significant increase of 211.41% year-over-year, primarily due to expenses related to the development of Ceftriaxone Sodium[6]. - The company reported a significant increase in intangible assets, which rose by 106.90% to ¥63,181,546.31, mainly due to the recognition of new products such as Celecoxib capsules[6]. - The company received approval for the drug registration certificate for Celecoxib capsules and the supplementary application approval for Cefminox sodium injection, indicating progress in new product development[16]. Cash Flow - The net cash flow from operating activities for the first nine months of 2021 was ¥24,600,318.25, a substantial increase of 291.42% compared to the same period last year[6]. - Cash flow from operating activities generated a net inflow of CNY 24,600,318.25, a turnaround from a net outflow of CNY 12,850,917.45 in the same period last year[27]. - The company incurred a net cash outflow from investing activities of CNY 24,111,859.37, compared to CNY 41,079,151.11 in the previous year, showing a decrease in outflow by approximately 41.2%[27]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 36,314[8]. - Southwest Synthetic Pharmaceutical Group Co., Ltd. holds 28.58% of shares, totaling 170,356,260 shares[8]. - Peking University Medical Industry Group Co., Ltd. holds 11.80% of shares, totaling 70,328,949 shares[8]. - The top ten shareholders include Chongqing Yangtze Pharmaceutical Factory with 1.21% (7,184,250 shares) and Beijing Zhengquan Holdings Co., Ltd. with 0.54% (3,225,346 shares)[8]. Corporate Governance - The company has completed the election of the 10th Board of Directors and Supervisory Board, with Song Jinsong elected as the chairman[11]. - The company has engaged a new board secretary, Yuan Yufei, as part of its management changes[12]. - The company has revised its Articles of Association as approved in the 2020 annual general meeting[12]. Restructuring - The company is in the process of restructuring, with a deadline for the restructuring plan extended to April 30, 2021[9]. - The restructuring investor consortium includes Zhuhai Huafa Group, China Ping An Insurance, and Shenzhen Special Zone Development Group[10]. - The company is in the process of restructuring its ownership, with Ping An Life becoming the controlling shareholder, holding 40.40% of the total shares[15].